Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide

What Was Tested

This randomized controlled trial paper looks at Exenatide and Insulin Glargine in the context of fatty liver & elevated liver enzymes.

However, their interaction on clinical grounds needs to be further elucidated.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

DMT2 patients with abnormal aminotransferases were screened for NAFLD and subjected to liver biopsy (group A, n=17).

A subgroup of patients (n=110), after assessed for eligibility criteria, was blindly randomized to receive either 6-month exenatide supplementation on glargine insulin (group B) or intense, self-regulated, insulin therapy alone (group C).

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.

What Was Measured

Topics PubMed links to this paper include Adiponectin, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin and Hypoglycemic Agents.

The authors tagged it with the keywords Diabetes mellitus type 2, Glucagon-like peptide-1 and Non-alcoholic fatty liver disease.

What This Means in Plain Language

The paper is a randomized study of Exenatide and Insulin Glargine in people with fatty liver & elevated liver enzymes.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Diabetes research and clinical practice), a journal based in Ireland.

More context: the Exenatide compound page and the Insulin Glargine compound page, Fatty liver & elevated liver enzymes research.